US Global Jets ETF vs uniQure N.V. Ordinary Shares — how do they compare? US Global Jets ETF trades at $25.99 (market cap $766.85M), while uniQure N.V. Ordinary Shares trades at $21.53 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is more actively traded (3,323,243 versus 3,093,704). Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| JETS | QURE | |
|---|---|---|
Market Cap | $766.85M | $1.45B |
Volume | 3,093,704 | 3,323,243 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $70.59 |
52-Week Low | $23.64 | $9.03 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
JETS (U.S. Global Jets ETF) trades at $26.80, down 0.81% amid bearish technical signals with 17 sell indicators versus 5 buy signals. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though oversold RSI levels suggest potential near-term support. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
Outlook remains cautious given fuel price volatility and airline earnings uncertainty. Investment opportunity exists for contrarians betting on travel recovery, but risks include sustained high oil prices and weaker-than-expected demand. The ETF's focus on pure-play airlines increases sensitivity to operational cost pressures compared to diversified aerospace funds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →